- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05206500
NextGen - Clinical Implication of Next Generation Sequencing
April 9, 2024 updated by: Wake Forest University Health Sciences
Clinical Implication of Next Generation Sequencing of Urinary Bacteria in Patients With Low Colony Forming Units of Bacteria in Traditional Urine Culture
Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes.
Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in patients with Colony Count of less than 10,000 and more than zero.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Bacterial sensitivity test for different antibiotics are the most important guide for treatment of patients with UTI.
Unfortunately, for patients with less than 10,000 Colony Count (CC), usually no sensitivity test is done and there is not any guide for appropriate antibiotic therapy for this group.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Majid Mirzazadeh, MD
- Phone Number: 336-716-4310
- Email: mmirzaza@wakehealth.edu
Study Contact Backup
- Name: Sachin N Vyas, MS, PhD
- Phone Number: 336-713-4098
- Email: svyas@wakehealth.ed
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Health Sciences
-
Contact:
- Majid Mirzazadeh, MD
- Phone Number: 336-716-4310
- Email: mmirzaza@wakehealth.edu
-
Contact:
- Sachin N Vyas, MS, PhD
- Phone Number: 336-713-4098
- Email: svyas@wakehealth.edu
-
Principal Investigator:
- Majid Mirzazadeh, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female at least 18 years of age
- U/C (Urinary Culture) growth of <10,000 Colony-Forming Units (CFU)
- Understanding and acceptance of the need to return for all scheduled follow-up visits
- Able to give informed consent
Exclusion Criteria:
- Catheter in use (Foley or suprapubic or intermittent)
- Not able to provide clean midstream urine
- Antibiotic consumption in the past 2 weeks before signing the consent
- Pregnant or Planning to Conceive
- Incarcerated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Symptomatic Patients with low Colony Count
Patients with positive urinalysis, symptomatic, and Urine Culture Colony Count <10,000 to be treated based on Next Generation Sequencing result.
|
FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC >0 and <10,000
Other Names:
Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Next Generation Sequencing (NGS) Results (numbers of colony count (CC)) of Urinary Tract Infection (UTI)
Time Frame: Baseline
|
NGS Ability to Detect Bacteria among patients with UTI Colony Count (CC) of Bacteria <10,000.
Result Measure: NGS CC 100 to 10,000
|
Baseline
|
Next Generation Sequencing (NGS) Results (numbers of colony count (CC)) of Urinary Tract Infection (UTI)
Time Frame: 3 Weeks Post-Treatment
|
NGS Ability to Detect Bacteria among patients with UTI Colony Count (CC) of Bacteria <10,000, Result Measure: NGS CC 100 to 10,000
|
3 Weeks Post-Treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Improvement (King's Questionnaire Outcome measure) in UTI symptoms with CC <10,000
Time Frame: Baseline
|
NGS result focused antibiotic treatment and symptom outcome with the measurement of King's Questionnaire Outcome.
Result Measure: Mild, Moderate, and Severe UTI symptoms in last 12 and 24 hours on 7 questions with no symptoms as "0", Mild as "1", Moderate as "2", and Severe as "3"
|
Baseline
|
Patient Improvement (King's Questionnaire Outcome measure) in UTI symptoms with CC <10,000
Time Frame: 3 Weeks Post-Treatment
|
NGS result focused antibiotic treatment and symptom outcome with the measurement of King's Questionnaire Outcome.
Result Measure: Mild, Moderate, and Severe UTI symptoms in last 12 and 24 hours on 7 questions with no symptoms as "0", Mild as "1", Moderate as "2", and Severe as "3"
|
3 Weeks Post-Treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Majid Mirzazadeh, MD, Wake Forest Health Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 17, 2022
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
January 7, 2022
First Submitted That Met QC Criteria
January 11, 2022
First Posted (Actual)
January 25, 2022
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Anti-Infective Agents, Urinary
- Linezolid
- Metronidazole
- Ampicillin
- Anti-Bacterial Agents
- Clindamycin
- Amoxicillin
- Fluoroquinolones
- Nitrofurantoin
- Tetracycline
- Penicillins
- Fosfomycin
- Cephalosporins
Other Study ID Numbers
- IRB00073565
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual Participant Data are not planned to be shared.
All subject related information will be available under the subject ID.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infections
-
GlaxoSmithKlineCompletedInfections, Urinary TractEgypt
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Shandong Branden Med.Device Co.,LtdTerminatedUrinary Tract Infection | Urinary CathetersChina
-
Inmunotek S.L.CompletedUrinary Tract Infection BacterialSpain, United Kingdom
-
AbbottCompletedUrinary Tract Infections (UTIs)Pakistan
-
Newcastle-upon-Tyne Hospitals NHS TrustCambridge University Hospitals NHS Foundation Trust; University of Southampton and other collaboratorsCompletedUrinary Tract Infections, RecurrentUnited Kingdom
-
Hospital del Río HortegaCompletedUrinary Tract Infection
-
Assaf-Harofeh Medical CenterNanovibronixUnknown
-
Bergaliden BarnavårdscentralCompleted
Clinical Trials on Antibiotic
-
Mahidol UniversityCompletedBacteriuria | Kidney Transplantation | Asymptomatic InfectionsThailand
-
The Cleveland ClinicCompletedOveractive Bladder | Urge Incontinence | Urinary Incontinence, Urge | Overactive Bladder SyndromeUnited States
-
Ruijin HospitalNot yet recruiting
-
University of Geneva, SwitzerlandCentre Hospitalier Universitaire Vaudois; Cantonal Hospital of St. GallenCompletedBacteraemia Caused by Gram-Negative BacteriaSwitzerland
-
Assistance Publique - Hôpitaux de ParisRecruitingKidney Transplant Infection | Pyelonephritis AcuteFrance
-
Thomas BenfieldRecruitingUrinary Tract Infection Bacterial | Gram-negative BacteremiaDenmark
-
Spanish Society of Family and Community MedicineCompletedRespiratory Tract Infections | Infectious DiseasesSpain
-
Assistance Publique - Hôpitaux de ParisBioMérieuxRecruiting
-
Nantes University HospitalRecruitingVentilator Associated Pneumonia | Critical Care | Antibiotic TherapyFrance
-
ARCIM Institute Academic Research in Complementary...Gemeinschaftskrankenhaus Herdecke, GermanyRecruitingCommunity Acquired Pneumonia in Children | Antibiotic StewardshipGermany